ArticleJournal of translational medicine2026
microRNA-204 as a crucial cancer stem cell related miRNA inhibits stemness of gastric cancer by targeting CD44 and EPCAM.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer stem cells (CSCs) and normal stem cells share key properties such as self-renewal and differentiation capacity, yet the microRNAs (miRNAs) that are differentially expressed between them remain poorly characterized. This study aimed to identify such miRNAs, with a focus on microRNA-204 (miR-204), and to investigate its functional role and regulatory mechanisms in gastric cancer.
methodsUsing miRNA microarray data from public databases (GEO and TCGA), we identified miR-204 as a stemness-related miRNA. Its expression was validated in clinical gastric cancer tissues and cell lines. Functional assays, including colony formation, Transwell, tumorsphere formation, and extreme limiting dilution analysis, were performed to assess the effects of miR-204 on proliferation, metastasis, and stemness. Luciferase reporter assays confirmed direct targeting of CD44 and EPCAM. The role of TP53 in miR-204 maturation was investigated using TP53-knockout mice and TP53 overexpression cell models.
resultsmiR-204 was identified as a crucial miRNA, upregulated in normal stem cells but significantly downregulated in CSCs and multiple human cancers, including gastric cancer. Low miR-204 expression correlated with advanced TNM stage and poor overall survival in gastric cancer patients. Restoring miR-204 expression potently inhibited gastric cancer cell proliferation, metastasis, and stemness properties. Mechanistically, miR-204 directly targeted and suppressed the expression of two key CSC regulators, CD44 and EPCAM. Furthermore, we discovered that TP53 mutation is a major cause of miR-204 downregulation, and demonstrated that TP53 promotes the maturation of miR-204 rather than its primary transcription.
conclusionsOur study unveils miR-204 as a pivotal tumor suppressor that distinguishes CSCs from normal stem cells. It functions by targeting the CD44/EPCAM axis to inhibit gastric cancer stemness, a process governed by a novel TP53-miR-204 regulatory circuit. These findings position miR-204 as a promising prognostic biomarker and therapeutic target for eradicating CSCs in gastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.